2025 HCPCS code J9033

Injection, bendamustine HCl (Treanda), 1 mg

Use J9033 only for the Treanda brand of bendamustine HCl. Do not report administration separately unless payer guidelines allow. If a partial vial is discarded, modifier JW may be applicable.

Modifiers such as JW (Drug amount discarded/not administered to any patient) may be applicable.

Medical necessity must be established for the underlying diagnosis (CLL or B-cell NHL) for which the bendamustine HCl is being administered. Documentation should support the patient's condition and the appropriateness of chemotherapy treatment.

Administering bendamustine HCl intravenously as prescribed, monitoring patient for adverse reactions, and adjusting dosage based on patient's hematologic and non-hematologic tolerance.

IMPORTANT For Bendeka brand use J9034, for Belrapzo brand use J9036

In simple words: This code represents one milligram of Treanda, a chemotherapy drug used to treat certain blood cancers.It's given through an IV and the dosage depends on the type of cancer and the patient's overall health.

Bendamustine HCl (Treanda) is an alkylating agent used in chemotherapy to treat certain types of cancers such as chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin's lymphoma.It works by killing cancer cells or slowing their growth.The usual dosage for CLL is 100 mg/m2 given intravenously over 30 minutes on days 1 and 2 of a 28-day cycle, up to 6 cycles. For indolent B-cell non-Hodgkin's lymphoma, 120 mg/m2 is administered intravenously over 60 minutes on days 1 and 2 of a 21-day cycle for up to 8 cycles. Dosages may be adjusted based on patient's hematologic and non-hematologic toxicity.Treanda is supplied as 100 mg of bendamustine HCl lyophilized powder in single-dose vials. This code is reported per 1 mg administered.

Example 1: A patient with CLL receives 100 mg/m2 of Treanda IV over 30 minutes on days 1 and 2 of a 28-day cycle. The code J9033 is reported for each 1 mg administered., A patient with indolent B-cell NHL receives 120 mg/m2 of Treanda IV infused over 60 minutes on days 1 and 2 of a 21-day cycle.J9033 is reported per each 1 mg given., Due to adverse effects, the physician reduces the dose of Treanda for a patient. The code J9033 is still reported for each 1 mg of the adjusted dose administered.

Diagnosis, dose administered, route of administration, date of administration, and any adverse reactions.

** J9033 represents the supply of the drug only. Check payer guidelines for administration coding.

  • Payment Status: Active
  • Specialties:Oncology, Hematology
  • Place of Service:Office, Inpatient Hospital, Outpatient Hospital, Independent Clinic, Federally Qualified Health Center
** Only Enterprise users with EHR integration can access case-specific answers. Click here to request access.